dovato
viiv healthcare b.v. - dolutegravir nātrija, lamivudīnu - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - dovato ir indicēts, lai ārstētu cilvēku imūndeficīta vīrusa tips 1 (hiv-1) infekciju pieaugušajiem un pusaudžiem virs 12 gadiem, kas sver vismaz 40 kg, nav zināms vai ir aizdomas par pretestību integrase inhibitoru klases, vai lamivudīnu.
qtrilmet
astrazeneca ab - metformīns hidrohlorīds, saxagliptin, dapagliflozin - cukura diabēts, 2. tips - cukura diabēts - qtrilmet ir norādīts pieaugušajiem vecumā no 18 gadiem un vecāki ar 2. tipa cukura diabētu:lai uzlabotu glycaemic kontroles, ja metformīns ar vai bez sulfonilurīnvielas pamata (su) un vai nu saxagliptin vai dapagliflozin nenodrošina pietiekamu kontroles glycaemic. ja jau tiek ārstēti ar metformīnu un saxagliptin un dapagliflozin.
drovelis
gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - dzimumhormoni un dzimumsistēmas modulatori dzimumorgānu sistēma, - oral contraceptive.
lydisilka
estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - dzimumhormoni un dzimumsistēmas modulatori dzimumorgānu sistēma, - mutes trakta kontracepcija. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
pestigon
norbrook laboratories limited, Īrija - fipronils - šķīdums pilināšanai uz ādas - 50 mg - kaķi
colhot 300 mg/5 mg/20 mg pulveris iekšķīgi lietojama šķīduma pagatavošanai paciņā
richard bittner ag, austria - paracetamolum, phenylephrini hydrochloridum, skābes ascorbicum - pulveris iekšķīgi lietojama šķīduma pagatavošanai paciņā - 300 mg/5 mg/20 mg
eucreas
novartis europharm limited - vildagliptin, metformīns hidrohlorīds - cukura diabēts, 2. tips - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.